GCLLSG HO133 NHL
- HO133 MCL
- Working group party:
- 1st Line
- Level D
- Included patients:
- Active sites:
autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction in Generalized mantle cell Lymphoma – a randomized European mcl network trial.
Target recruitment (870 patients) is achieved so enrolment has been stopped. Already randomized patients will continue according to protocol.
Registration procedure is changed because 850 of 870 patients are included. From now on if you have a potential patient for the study, an email notification should be send to the sponsor in order to reserve a slot. Please see the instructions in the email send on 21st of October 2020.
Study documents regarding AM1 are uploaded on the HOVON website.
The first site in Belgium is opened for patient inclusion.
The first site in the Netherlands opened for patient inclusion.
HOVON Lymphoma working group has decided to implement the rituximab maintenance. Therefore, all Dutch HOVON sites should implement the maintenance (every 2 months up to 3 years) to all three study arms. Belgian sites will follow once the national reimbursement for rituximab is possible. Please also see the sent newsletters in the study documentation.
Start Up meeting for participating HOVON sites was held in Utrecht.
Participants Inquiry is sent to all HOVON sites. Planning is that study will first start in Germany (Q4 2015) after which HOVON will join with 25-30 sites in NL+BE.
- Prospective randomized Phase III study
- Monitoring Type:
- Study Specific
The primary objective of the trial is to establish one of three study arms, R-CHOP/R-DHAP followed by ASCT (control arm A), R-CHOP+ibrutinib /R-DHAP followed by ASCT and followed by ibrutinib maintenance (experimental arm A+I), and R-CHOP+ibrutinib /R-DHAP followed by ibrutinib maintenance (experimental arm I) as future standard based on the comparison of investigator-assessed failure-free survival (FFS).
- To compare the efficacy of the three treatment arms in terms of secondary efficacy endpoints
- To determine the safety and tolerability of ibrutinib during induction immunochemotherapy and during maintenance and to compare the safety profile of the three treatment arms in terms of secondary toxicity endpoints
- To compare feasibility of ASCT in arm A+I vs. arm A
- To compare minimal residual disease status between the three treatment groups
- To determine the impact of ibrutinib during induction immuno-chemotherapy and during maintenance therapy on the minimal residual disease status
- To determine the prognostic value of minimal residual disease status
- To determine the prognostic value of positron emission tomography with fluorine 18-fluorodeoxyglucose
- To determine clinical and biological prognostic and predictive factors
- To determine the role of total body irradiation (TBI) in ASCT conditioning
- Inclusion Criteria:
- *Histologically confirmed diagnosis of MCL according to WHO classification
- Suitable for high-dose treatment including high-dose Ara-C
- Stage II-IV (Ann Arbor)
- Age ≥ 18 years and ≤ 65 years
- Previously untreated MCL
- At least 1 measurable lesion; in case of bone marrow infiltration only, bone marrow aspiration and biopsy is mandatory for all staging evaluations.
- ECOG/WHO performance status ≤ 2
- The following laboratory values at screening (unless related to MCL):
- Absolute neutrophil count (ANC) ≥1000 cells/µL
- Platelets ≥100,000 cells/µL
- Transaminases (AST and ALT) ≤3 x upper limit of normal (ULN)
- Total bilirubin ≤2 x ULN unless due to known Morbus Meulengracht [Gilbert-Meulengracht-Syndrome])
- Creatinine ≤2 mg/dL or calculated creatinine clearance ≥50 mL/min
- Written informed consent form according to ICH/EU GCP and national regulations
- Sexually active men and women of child-bearing potential must agree to use one of the highly effective contraceptive methods (combined oral contraceptives using two hormones, contraceptive implants, injectables, , intrauterine devices, sterilized partner) together with one of the barrier methods (latex condoms, diaphragms, contraceptive caps) while on study; this should be maintained for 90 days after the last dose of study drug and 12 months after the last dose of rituximab
- Exclusion Criteria:
- Major surgery within 4 weeks prior to randomization.
- Requires anticoagulation with warfarin or equivalent vitamin K antagonists (e.g. phenprocoumon).
- History of stroke or intracranial hemorrhage within 6 months prior to randomization.
- Requires treatment with strong CYP3A4/5 inhibitors.
- Any life-threatening illness, medical condition, or organ system dysfunction which, in the investigator’s opinion, could compromise the subject’s safety, interfere with the absorption or metabolism of ibrutinib capsules, or put the study outcomes at undue risk.
- Vaccinated with live, attenuated vaccines within 4 weeks prior to randomization.
- Known CNS involvement of MCL
- Clinically significant hypersensitivity (e.g., anaphylactic or anaphylactoid reactions to the compound of ibrutinib itself or to the excipients in its formulation)
- Known anti-murine antibody (HAMA) reactivity or known hypersensitivity to murine antibodies
- Previous lymphoma therapy with radiation, cytostatic drugs, anti-CD20 antibody or interferon except prephase therapy outlined in this trial protocol
- Serious concomitant disease interfering with a regular therapy according to the study protocol:
- Cardiac (Clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of Screening, or any Class 3 (moderate) or Class 4 (severe) cardiac disease as defined by the New York Heart Association Functional Classification E10or LVEF below LLN )
- Pulmonary (chronic lung disease with hypoxemia)
- Endocrinological (severe, not sufficiently controlled diabetes mellitus)
- Renal insufficiency (unless caused by the lymphoma): creatinine > 2x normal value and/or creatinine clearance < 50 ml/min)
- Impairment of liver function (unless caused by the lymphoma): transaminases > 3x normal or bilirubin > 2,0 mg/dl unless due to Morbus Meulengracht (Gilbert-Meulengracht-Syndrome)
- Positive test results for chronic HBV infection (defined as positive HBsAg serology) (mandatory testing). Patients with occult or prior HBV infection (defined as negative HBsAg and positive total HBcAb) may be included if HBV DNA is undetectable, provided that they are willing to undergo monthly DNA testing. Patients who have protective titers of hepatitis B surface antibody (HBSAb) after vaccination are eligible.
- Positive test results for hepatitis C (mandatory hepatitis C virus [HCV] antibody serology testing). Patients positive for HCV antibody are eligible only if PCR is negative for HCV RNA
- Patients with known HIV positive infection (mandatory test)
- Prior organ, bone marrow or peripheral blood stem cell transplantation
- Concomitant or previous malignancies within the last 3 years other than basal cell skin cancer or in situ uterine cervix cancer
- Pregnancy or lactation
- Any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow up schedule
- Subjects not able to give consent
- Subjects without legal capacity who are unable to understand the nature, scope, significance and consequences of this clinical trial
- Participation in another clinical trial within 30 days before randomization in this study.
Via eCRF system of sponsor KU Munich:
Regular interim analyses in approximately half-yearly schedule, triggered by the regular meetings of the European MCL Network that take place twice a year.
Ziekenhuizen die deelnemen aan het onderzoek staan benoemd op de HOVON website bij het onderzoek. Het kan zijn dat uw ziekenhuis niet genoemd wordt, maar wel aan het onderzoek deelneemt. Informeer hiernaar bij uw arts.